Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)

NCT02242097 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02242097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02242097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
January 12, 2015
Completion date
January 5, 2023
Enrollment
37 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

contiguous stage ii mantle cell lymphoma, noncontiguous stage ii mantle cell lymphoma, stage i mantle cell lymphoma, stage iii mantle cell lymphoma, stage iv mantle cell lymphoma